⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
Exendin-4 (Nasal Spray)
Exendin-4 (a GLP-1 analog) is being studied in a research-only nasal formulation for its potential central action on satiety and weight regulation.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Mechanism of Action
Exendin-4 acts as a GLP-1 receptor agonist. The subcutaneous form (Exenatide) has a documented effect on satiety and glucose regulation. Nasal administration is being investigated as a potential means of central action, without sufficient clinical documentation yet.
Overview
- GLP-1 receptor agonist
- Nasal formulation is investigational
- Only the subcutaneous form (Exenatide) is approved
- No usage instructions provided
Intranasal Delivery — Research Data
- Exendin-4 is being studied in a research-only nasal formulation for its potential central action on hunger/satiety.
- The approved form (Exenatide/Byetta) is administered only subcutaneously.
- Nasal bioavailability has not been fully documented.
Investigational
The intranasal form is at an investigational stage. Available data is limited.
Dosing Table — Exendin-4 Nasal Spray (Investigational)
| Period | Dose | Notes |
|---|---|---|
| Investigational | Not established | — |
Data on nasal administration is limited. Investigational stage only.
Formulation Notes
No self-preparation instructions provided
- There is no approved nasal formulation.
- Research studies use specially prepared solutions.
Storage After Opening
- Investigational stage — no commercial formulations exist.
Dosing Protocol
- There is no established protocol for nasal administration.
Storage Instructions
- Investigational stage — no commercial formulations exist.
Important Notes
- Nasal Exendin-4 is in an early investigational stage.
- The approved form (Exenatide) is administered only subcutaneously.
- No instructions for use or self-preparation are provided.
Benefits & Side Effects
Potential Benefits
- Potential central action on satiety (investigational)
- Glucose regulation (documented for subcutaneous form)
Potential Side Effects
- Nausea (known side effect of GLP-1 agonists)
- Nasal irritation (not yet documented)
References
Intranasal Peptide Delivery: Complete Guide
Bioavailability, absorption factors, comparison with injectables, and limitations of nasal delivery.
Research Limitations
The data on this page is strictly educational. No self-preparation or self-administration instructions are provided.
External Sources & Regulatory Status
Regulatory Approvals
Byetta® / Bydureon® · Type 2 diabetes (2005)
Byetta® / Bydureon® · Type 2 diabetes (2006)
FDA + EMA approved as exenatide (a synthetic form of exendin-4) for type 2 diabetes.
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →